(Q36658946)

15 August 2017

1 reference

title

Estrogen therapy for postmenopausal osteoporosis (English)

1 reference

15 August 2017

0 references

1 reference

Lorraine A Fitzpatrick

series ordinal

1 reference

15 August 2017

publication date

1 August 2006

1 reference

Arquivos Brasileiros de Endocrinologia e Metabologia

15 August 2017

published in

1 reference

15 August 2017

1 reference

15 August 2017

1 reference

15 August 2017

page(s)

705-719

1 reference

Fragility fracture-related direct medical costs in the first year following a nonvertebral fracture in a managed care setting

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Epidemiology and outcomes of osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Vasomotor symptom relief versus unwanted effects: role of estrogen dosage

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Estrogen receptor-related receptor alpha: a mediator of estrogen response in bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Pathogenesis of osteoporosis: concepts, conflicts, and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Role of RANK ligand in mediating increased bone resorption in early postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Effect of Testosterone and Estradiol in a Man with Aromatase Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Relative contributions of aging and estrogen deficiency to postmenopausal bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Role of estrogens in the management of postmenopausal bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Endogenous levels of serum estradiol and sex hormone binding globulin determine bone mineral density, bone remodeling, the rate of bone loss, and response to treatment with estrogen in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Bone loss and bone size after menopause

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Long term hormone therapy for perimenopausal and postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

How many women lose bone mineral density while taking hormone replacement therapy? Results from the Postmenopausal Estrogen/Progestin Interventions Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Bone response to termination of oestrogen treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Changes in bone density and turnover after alendronate or estrogen withdrawal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Postmenopausal hormone replacement therapy: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Differential Genetic Effects of ESR1 Gene Polymorphisms on Osteoporosis Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

Bone adaptation requires oestrogen receptor-α

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302006000400016

10.1590/S0004-27302006000400016

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference